The company will advance two atopic dermatitis antibody candidates towards human trials in 2027. Infinimmune Raises $75M For Clinical DevelopmentInfinimmune has raised $75 million in Series A funding to advance its antibody therapeutics pipeline. Its latest round reflects growing investor interest in human-derived antibody discovery technologies. Infinimmune describes it as a potential first-in-class monoclonal antibody for atopic dermatitis. Merck Partnership Strengthens Platform ValidationIn March 2026, Infinimmune entered a multi-target antibody discovery collaboration with Merck.